Psychoses Clinical Trial
Official title:
Oxidative Cell Injury: First Episode Psychotic Patients
Patients experiencing a first episode of psychosis may have brain cell damage due to a chemical process called oxidation. This study will compare patients with psychosis to healthy volunteers to determine if there are differences in their blood that reflect oxidative brain cell damage.
Preliminary research indicated that impaired antioxidant defense and increased lipid
peroxidation is associated with brain changes during the onset of psychosis. Oxidative cell
injury may contribute to poor outcomes in some patients. This study will define the extent
and nature of oxidative cell injury that is associated with psychopathology at the onset of
psychosis.
Participants in this study will be patients at the D. D. Eisenhower Army Medical Center who
are experiencing a psychotic episode for the first time. Patients will be compared with 40
healthy volunteers (control group) matched with patients for age, gender, education, ethnic
background, and occupational status. Patients and volunteers will have blood tests to
determine the level of oxidative cell injury. Tests will be performed at onset of psychosis,
and after 6 and 12 weeks of neuroleptic drug treatment. Medical histories and MRI scans will
be used to examine the relationship of the laboratory tests to the clinical presentation.
;
Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01196858 -
Duration of Untreated Psychosis (DUP) and Pathways to Care in Nordland
|
N/A | |
Completed |
NCT00159120 -
Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
|
Phase 4 | |
Completed |
NCT00159133 -
Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
|
Phase 4 | |
Completed |
NCT00087542 -
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
|
Phase 2 | |
Completed |
NCT00095810 -
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
|
Phase 4 | |
Recruiting |
NCT00752960 -
DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics
|
N/A | |
Completed |
NCT00469365 -
Pharmacy Interventions to Improve Chronic Disease Medication Refill
|
Phase 3 | |
Completed |
NCT00491569 -
Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
|
Phase 2 | |
Completed |
NCT00204061 -
Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis
|
Phase 4 | |
Completed |
NCT00328276 -
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
|
Phase 2 | |
Withdrawn |
NCT00276263 -
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia
|
Phase 2 | |
Active, not recruiting |
NCT00260273 -
Access, Detection and Psychological Treatments
|
N/A | |
Completed |
NCT00960219 -
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
|
Phase 2 | |
Completed |
NCT03609515 -
Patient-controlled Admissions in Inpatient Mental Health Services
|
N/A |